Costin G, Kogut M D, Hyman C, Ortega J A
Diabetes. 1977 Mar;26(3):230-40. doi: 10.2337/diab.26.3.230.
To investigate the development of diabetes mellitus in patients with thalassemia major, plasma glucose and immunoreactive insulin (IRI) levels following oral glucose and intravenous tolbutamide and glucose disappearance rates following intravenous insulin were measured in 10 patients before and during five years on a high transfusion program (HTP). Plasma immunoreactive glucagon (IRG) levels following oral glucose, intravenous insulin, and arginine were measured during the sixth year. Serial percutaneous liver biopsies were performed on seven patients. The oral glucose tolerance tests (OGAT) and mean peak IRI levels were normal in nine of 10 patients before HTP. After HTP was begun a progressive deterioration of OGTT occurred despite normal IRI levels. Following tolbutamide, the mean per cent fall in plasma glucose in the patients before HTP was significantly less than in controls (p less than 0.01) and similar to that of controls during five years of HTP in spite of higher than normal peak IRI levels. Of seven survivors after six years of HTP, three had normal OGTT and four had chemical diabetes; mean peak IRI levels were normal, but fasting IRG levels were significantly higher than in controls (p less than 0.05). In all seven patients, plasma IRG failed to increase following insulin-induced hypoglycemia and was significantly higher than in controls after arginine (p less than 0.01); after oral glucose, plasma IRG fell significantly below that of fasting only in the patients with chemical diabetes (p less than 0.03). Following intravenous insulin, the mean per cent fall in glucose before and during HTP was significantly less than in controls (p less than 0.01). Hemosiderosis and cirrhosis were present in all biopsied patients. Four patients died; two had chemical and two had nonketotic insulin-dependent diabetes. These data suggest that diabetes mellitus occurs frequently in patients with thalassemia on HTP and that insulin resistance and hyperglucagonemia, possibly due to cirrhosis, are important etiologic factors.
为研究重型地中海贫血患者糖尿病的发生情况,我们对10例患者在高输血方案(HTP)实施前及实施5年期间,测定了口服葡萄糖和静脉注射甲苯磺丁脲后的血浆葡萄糖和免疫反应性胰岛素(IRI)水平,以及静脉注射胰岛素后的葡萄糖消失率。在第6年测定了口服葡萄糖、静脉注射胰岛素和精氨酸后的血浆免疫反应性胰高血糖素(IRG)水平。对7例患者进行了系列经皮肝活检。10例患者中9例在HTP前口服葡萄糖耐量试验(OGAT)和平均IRI峰值水平正常。开始HTP后,尽管IRI水平正常,但OGTT仍逐渐恶化。甲苯磺丁脲给药后,HTP前患者血浆葡萄糖的平均下降百分比显著低于对照组(p<0.01),尽管IRI峰值水平高于正常,但在HTP的5年期间与对照组相似。HTP 6年后的7例幸存者中,3例OGTT正常,4例患有化学性糖尿病;平均IRI峰值水平正常,但空腹IRG水平显著高于对照组(p<0.05)。在所有7例患者中,胰岛素诱导的低血糖后血浆IRG未能升高,精氨酸后显著高于对照组(p<0.01);口服葡萄糖后,仅化学性糖尿病患者的血浆IRG显著低于空腹水平(p<0.03)。静脉注射胰岛素后,HTP前和期间葡萄糖的平均下降百分比显著低于对照组(p<0.01)。所有活检患者均有含铁血黄素沉着症和肝硬化。4例患者死亡;2例患有化学性糖尿病,2例患有非酮症胰岛素依赖型糖尿病。这些数据表明,接受HTP的地中海贫血患者经常发生糖尿病,胰岛素抵抗和高胰高血糖素血症可能由于肝硬化,是重要的病因因素。